Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma

NCT02594163 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT02594163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02594163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2015
Completion date
September 30, 2017
Enrollment
25 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma refractory, follicular b-cell non-hodgkin's lymphoma